Three long-acting HIV antibodies with planned ART breaks for children treated early in Botswana
A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana
This project gives three long-lasting HIV antibodies to children who started treatment early and pauses their regular HIV pills to test whether the antibodies can keep the virus under control.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard University D/b/a Harvard School of Public Health NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11126770 on NIH RePORTER |
What this research studies
If your child joins, they would receive infusions of three broadly neutralizing antibodies (bNAbs) on a scheduled rotation. While on the antibodies, doctors will pause the child’s daily antiretroviral therapy (an analytic treatment interruption) and closely monitor viral levels, safety, and immune signs. The study builds on an earlier Tatelo trial where two bNAbs kept virus suppressed without ART for many children, and it aims to improve on that by using three antibodies and a stepwise design. Visits and testing will take place at study clinics in Botswana with frequent monitoring to restart ART if needed.
Who could benefit from this research
Good fit: Children who started ART very early after infection, are currently receiving care and viral suppression, and are able to attend frequent clinic visits in Botswana would be the ideal candidates.
Not a fit: People who were not treated early, who are not currently virologically suppressed, who cannot safely stop ART, or who live outside the study region are unlikely to benefit from joining this trial.
Why it matters
Potential benefit: If successful, this approach could reduce time on daily ART, lower drug-related side effects during growth, and increase the chance of long-term virus control without continuous pills.
How similar studies have performed: A prior proof-of-concept Tatelo trial showed monthly dual bNAbs kept virus suppressed without ART for 24 weeks in 44% of early-treated children, while the three-antibody rotation here is a newer strategy.
Where this research is happening
Boston, United States
- Harvard University D/b/a Harvard School of Public Health — Boston, United States (Active)
Researchers
- Principal investigator: Shapiro, Roger L — Harvard University D/b/a Harvard School of Public Health
- Study coordinator: Shapiro, Roger L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.